VVT Medical (TSXv:VVTM) advances vein care with minimally invasive, office-based treatments that reduce procedural complexity, recovery time, and adverse effects.
Our proprietary products deliver precise, controlled therapy for patients with varying venous pathologies.
VVT’s product portfolio includes ScleroSafeTM and V-BlockTM, two synergistic, catheter-based solutions designed to treat the widest range of vein diameters in the market.
Leveraging a proprietary mechanochemical technology that combines controlled sclerosant injection and simultaneous vessel collapse and blood aspiration, our products deliver effective vein closure with minimal side effects.
This milestone marks a major regulatory achievement and formally establishes the pathway for the company’s entry into the U.S. market. The clearance enables VVT Medical to begin commercial activities in the United States, supporting broader adoption of its technology by physicians and advancing the company’s global growth strategy.
The conference provided an important opportunity to engage with physicians, exchange clinical insights, and take part in discussions shaping the future of venous care, alongside vascular surgeons, interventional radiologists, and phlebologists from around the world.
Led by Dr. Steve Elias with co-chairs Dr. Antonios Gasparis and Dr. Nicos Labropoulos, EVM stands out for its open, informal approach to real-world vein care. Live cases, candid discussions, and true cross-disciplinary exchange—less conference, more conversation.
Under the agreement, Medworks - a leading healthcare distributor in India - will be responsible for the marketing, sales, and distribution of the ScleroSafe™ platform across the Indian market, leveraging its established network and deep expertise in advanced healthcare technologies.
We were honored to welcome Prof. Ralf Kolvenbach, esteemed vascular surgeon and distinguished member of the VVT Medical Advisory Board, to our booth. We met with numerous interested distributors, physicians, and potential partners who were fascinated by our technology.
“That was painless!” was the patient’s first reaction. Huge thanks to Dr. Antonios Gasparis, System Chief of Vein Disease and the entire Northwell team for their trust and professionalism.
It marked the beginning of our next chapter as a publicly traded company and reinforced our commitment to advancing venous care through innovative, non-thermal, minimally invasive solutions.
ScleroSafe Study Published in Indian Journal of Vascular and Endovascular Surgery (2026). New clinical data from Holy Spirit Hospital and Medical Research Centre in Mumbai was published in the Indian Journal of Vascular and Endovascular Surgery, highlighting the use of ScleroSafe in patients with symptomatic varicose veins. The study demonstrated strong early vein closure rates and an excellent safety profile, reinforcing its potential as an effective non-thermal approach in modern venous care.
Read more# VVT Med Signs Distribution Agreement in Italy VVT Med signed an exclusive distribution agreement with Uber Ros S.p.A. for the commercialization of ScleroSafe™ in Italy, Vatican City and San Marino. The agreement, the Company’s largest European distribution partnership to date, further expands ScleroSafe’s presence in the European market. As part of the partnership, Uber Ros also joined VVT Med as an investor, reflecting its confidence in the technology and its commercial potential.
Read more
VVT Medical participated in Global Health Innovation Meets China, an international platform bringing together leading health-tech companies, investors, and partners from China, Europe, and the U.S. As part of the event, the Company took part in a dedicated health-tech roundtable focused on collaboration, market entry, and commercialization, presenting its non-thermal, anesthesia-free approach to venous disease and exploring opportunities for future partnerships in the Chinese and global markets.
ScleroSafe™ was featured at Vein University Grand Rounds, bringing together leading vein specialists and recognized opinion leaders in their respective fields. The session featured Dr. Lowell Kabnick, Dr. Anil Hingorani, Dr. V. Canata, Roxana Paetzold, and Dr. Tony Gasparis, who shared their perspectives on ScleroSafe™, including real-world experience, clinical outcomes, and procedural insights, as well as the growing role of non-thermal, anesthesia-free treatment options in contemporary vein care.
VVT Med has expanded its commercial presence in the Americas through a distribution and evaluation agreement with Antilles Medical, appointing the company as the exclusive distributor of ScleroSafe™ in the Dominican Republic. The partnership supports the introduction of ScleroSafe™ to local physicians and represents another step in VVT Med’s strategy to expand access to its minimally invasive, non-thermal technology for the treatment of venous disease.
Read moreVVT Med has expanded its European commercial presence through an exclusive distribution agreement with General Chemical Products S.A. (GCP), an established Greek medical technology company. The partnership will support the introduction and commercialization of ScleroSafe™ in Greece, further strengthening VVT Med’s European distribution network and expanding access to its minimally invasive, non-thermal technology for the treatment of venous disease.
Read moreVVT Med will settle CAD$212,939.76 in vendor debt through the issuance of 586,096 common shares, subject to TSX Venture Exchange approval and a four-month statutory hold. The company also granted 688,773 stock options and 912,519 Restricted Share Units to directors, employees, and advisory board members, and confirmed the British Columbia Securities Commission revoked its management cease trade order on July 2, 2026.
For more investor related news
